2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis AMX0114, Placebo - ALS | Phase 1 | Recruiting | Amylyx Pharmaceuticals Inc. | 48 | 2025-04-07 | 2026-04-14 |
| PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease 11C-MC1, 11C-PS13, 18f-florbetaben - Parkinson's Disease, Dementia | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 184 | 2021-08-17 | 2026-11-02 |
Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Cognitive Dysfunction (1) · Dementia (1) · Inflammation (1) · Motor Neuron Disease (1) · Parkinson Disease (1)
Central Nervous System Diseases (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Basal Ganglia Diseases (1) · Brain Diseases (1) · Cognition Disorders (1) · Mental Disorders (1) · Metabolic Diseases (1) · Movement Disorders (1) · Neurocognitive Disorders (1) · Neuromuscular Diseases (1) · Nutritional and Metabolic Diseases (1) · Parkinsonian Disorders (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
(11C)-MC1 (1) · 11C-PS13 (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1)
Amylyx Pharmaceuticals Inc. (1) · National Institute of Mental Health (NIMH) (1)
United States (2) · Canada (1)